Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyProtocol groupTransplantationDiseaseHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular grade IIIbSubgroupICD10C81.-C82.-C82.7C82.9C83.1C83.3C84.6MeSHLymphoma, Mantle-CellSequenceChemotherapyChemo-substanceBendamustineCytarabineEtoposideMelphalanChemo-substanceBendamustineCytarabineEtoposideMelphalanChemo-substanceBendamustineCytarabineEtoposideMelphalanChemo-substanceBendamustineCytarabineEtoposideMelphalanNo. Substances4 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronNo. Substances4Protocol classificationTherapy classificationalternativeIntensityHigh dose myeloablativeTherapy indicationRelapse therapyTherapy phaseconditioningTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO)Gastrointestinal ToxicityInfectionsOral MucositisPyrexia only studiesPublicationAuthorVisani GDiseaserefraktäres oder rezidivierendes NHL oder HL, Rituximab VortherapieOriginHematology and Stem Cell Transplant Center, Marche Nord Hospital, Pesaro, ItalyProtocols in Revision 1 protocol foundProtocols under revision.BeEAM - Bendamustine 100 / Etoposide 200 / Cytarabine 200 / Melphalan 140, prior to autologous Stem Cell Transplantation (PID879 V1.0)
